Xtant Medical Holdings, Inc. (XTNT)
$0.37+$0.05 (+16.36%) Today
Xtant Medical Holdings Inc is a medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures. Its products are used by orthopedic spine surgeons and neurosurgeons to treat a variety of spinal disorders in the cervical, thoracolumbar, and interbody spine. The company's biomaterial products include OsteoSponge, OsteoSponge SC, OsteoSelect Plus DBM putty, OsteoWrap, and the line of 3Demin products, as well as other allografts. It generates a majority of its revenue from the U.S.
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Grant or award | 8 | 2,585,343 | |
| Tax withholding / forfeiture | 3 | 45,830 |
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
22 Form 4 filings on record, the earliest from Oct 16, 2024, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Tyler Lipschultz - Director | Grant or award | Common Stock | 215,517 | $0.00 | - | |
| John K. Bakewell - Director | Grant or award | Common Stock | 215,517 | $0.00 | - | |
| Jonn R. Beeson - Director | Grant or award | Common Stock | 215,517 | $0.00 | - | |
| Abhinav Jain - Director | Grant or award | Common Stock | 215,517 | $0.00 | - | |
| Stavros G. Vizirgianakis - Director | Grant or award | Common Stock | 323,275 | $0.00 | - | |
| Mark A. Schallenberger - Officer | Grant or award | Common Stock | 450,000 | $0.00 | - | |
| Mark A. Schallenberger - Officer | Tax withholding / forfeiture | Common Stock | 7,070 | $0.31 | $2K | |
| Scott C. Neils - Officer | Grant or award | Common Stock | 400,000 | $0.00 | - | |
| Scott C. Neils - Officer | Tax withholding / forfeiture | Common Stock | 28,155 | $0.31 | $9K | |
| Sean E. Browne - Officer | Grant or award | Common Stock | 550,000 | $0.00 | - | |
| Sean E. Browne - Officer | Tax withholding / forfeiture | Common Stock | 10,605 | $0.31 | $3K | |
| Mark A. Schallenberger - Officer | Tax withholding / forfeiture | Common Stock | 7,709 | $0.58 | $4K | |
| Scott C. Neils - Officer | Tax withholding / forfeiture | Common Stock | 8,084 | $0.65 | $5K | |
| Abhinav Jain - Director | Grant or award | Common Stock | 158,228 | $0.00 | - | |
| John K. Bakewell - Director | Grant or award | Common Stock | 158,228 | $0.00 | - | |
| Tyler Lipschultz - Director | Grant or award | Common Stock | 158,228 | $0.00 | - | |
| Stavros G. Vizirgianakis - Director | Grant or award | Common Stock | 553,797 | $0.00 | - | |
| Sean E. Browne - Officer | Grant or award | Common Stock | 394,937 | $0.00 | - | |
| Sean E. Browne - Officer | Grant or award | Performance Stock Units (PSUs) | 789,874 | $0.00 | - | |
| Scott C. Neils - Officer | Grant or award | Common Stock | 263,291 | $0.00 | - | |
| Scott C. Neils - Officer | Grant or award | Performance Stock Units (PSUs) | 526,582 | $0.00 | - | |
| Jonn R. Beeson - Director | Grant or award | Common Stock | 158,228 | $0.00 | - | |
| Mark A. Schallenberger - Officer | Grant or award | Common Stock | 292,253 | $0.00 | - | |
| Mark A. Schallenberger - Officer | Grant or award | Performance Stock Units (PSUs) | 584,506 | $0.00 | - | |
| Sean E. Browne - Officer | Tax withholding / forfeiture | Common Stock | 10,605 | $0.63 | $7K | |
| Scott C. Neils - Officer | Tax withholding / forfeiture | Common Stock | 34,131 | $0.63 | $22K | |
| ORBIMED ADVISORS LLC - 10% Owner | Open-market sale | Common Stock | 56,004,974 | $0.42 | $23.52M | |
| ORBIMED ADVISORS LLC - 10% Owner | Open-market sale | Common Stock | 17,109,618 | $0.42 | $7.19M | |
| Sean E. Browne - Officer | Tax withholding / forfeiture | Common Stock | 105,442 | $0.59 | $62K |
Xtant Medical Holdings, Inc. (XTNT) had 8 insider filings in the last 90 days, with the most recent on 2026-08-18. The full record for XTNT runs to 22 Form 4 filings, the earliest from 2024-10-16. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
No insider purchases of XTNT were filed in the last 90 days.
No insider sales of XTNT were filed in the last 90 days. 2 sales are on record for this company.
This page tracks XTNT Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add XTNT to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
